This foundational mouse study examined whether restoring NAD+ with NMN could affect metabolic dysfunction caused by high-fat diet or aging.
NMN restored NAD+ in metabolic tissues and improved glucose intolerance in the studied mouse models. The authors also reported changes in hepatic insulin sensitivity, lipid profiles and gene-expression pathways related to oxidative stress, inflammation and circadian biology.
These results helped establish the modern NMN research field, but they are animal-model findings and cannot demonstrate treatment or anti-aging effects in people.
Key findings
High-fat feeding reduced NAD+ biosynthesis in metabolic organs in the mouse model.
NMN restored NAD+ and improved glucose intolerance in diet-induced diabetic mice.
NMN improved glucose intolerance and lipid profiles in age-associated diabetic mouse models.
Several molecular effects were linked partly to SIRT1-related signaling.
What it cannot establish
Mouse study, not a human clinical trial.
Disease models do not reproduce the full complexity of human type 2 diabetes or aging.
Doses and exposure cannot be directly translated to human supplement use.
Mechanistic and metabolic effects do not establish human clinical outcomes.
HealthspanX claim boundary: Mouse metabolic improvements do not establish that NMN prevents or treats diabetes, obesity, metabolic disease or aging in humans.
